Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Brainomix

Private
#Stroke#Pulmonary Fibrosis#Lung Cancer

Oxford University spinout developing AI-powered imaging biomarkers for stroke, lung cancer and pulmonary fibrosis. FDA cleared.

Company Info

Sector:AI / Machine Learning
Headquarters:Oxford, United Kingdom
Founded:2010
Website:www.brainomix.com/

Upcoming Milestones & Key Dates

2026-09
Conference

ERS Congress IPF trial results presentation

2026-Q4
Clinical

Phase 2a IPF imaging data expected

Clinical Development Pipeline

e-Stroke

Target: AI imaging analysis
Acute Ischemic Stroke
Preclinical
Phase 1
Phase 2
Phase 3
Approved

e-Lung

Target: AI imaging analysis
Interstitial Lung Disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

e-CTA

Target: AI imaging analysis
CT Angiography
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Michalis Papadakis

CEO & Co-Founder

Rajesh Gill

Chief Medical Officer

David Roalf

Chief Technology Officer

Careers & Job Openings

See all open roles

Various
Oxford, UK
Apply Now →